Method of treating humans with opioid formulations having extended controlled release
US6143322A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Apr 8, 1997 |
| Grant date | Nov 7, 2000 |
| Priority date | — |
| Expiry date | Apr 8, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Solid controlled-release oral dosage forms comprising a therapeutically effective amount of an opioid analgesic or a salt thereof which provide an extended duration of pain relief of about 24 hours, have a dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method at 100 rpm at 900 ml aqueous buffer (pH between 1.6 and 7.2) at 37.degree. C. of from about 12.5% to about 42.5% (by wt) opioid released after 1 hour, from about 25% to about 65% (by wt) opioid released after 2 hours, from about 45% to about 85% (by wt) opioid released after 4 hours, and greater than about 60% (by wt) opioid released after 8 hours, the in-vitro release rate being substantially independent of pH and chosen such that the peak plasma level of said opioid analgesic obtained in-vivo occurs from about 2 to about 8 hours after administration of the dosage form.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.